Event
Swedish Inflammatory Bowel Disease Conference (Virtual and In-Person)
presented by Swedish IBD
15 others would like to attend.
Register Now
Saturday, June 1, 2024 7 AM
-
4 PM
US/Pacific
Add to Calendar
Hyatt Regency - Bellvue, 900 Bellevue Way NE Bellevue WA 98004
Event info
OVERVIEW
The annual Swedish Inflammatory Bowel Disease Conference will review new and forthcoming medical and surgical therapeutic approaches in IBD and its associated manifestations, as well their impact on the current management of these conditions. The therapeutic landscape in IBD continues to evolve, resulting in rapid and dramatic changes to therapeutic algorithms and disease monitoring. The course will review the impact of positioning new therapeutics, optimization of medical therapy, disease management in the perioperative period, extraintestinal manifestations, dietary, nonpharmacologic therapies and multi-disciplinary approaches to complex clinical scenarios including strictures. It will also cover novel therapies including the advent of small molecules and their impact in the management of IBD patients.
Teaching methods include lecture/didactic, Q&A with faculty, panel discussion, case presentation and audience response system.
This year's keynote speaker is Dr. Remo Panaccione, Professor of Medicine, Director IBD Unit, University of Calgary, Canada. Dr/Prof Remo Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Calgary, Canada. He serves as the Dean of MD Admissions and Director of the IBD Fellowship Program.
This event is powered by Well-Assembled Meetings.
TARGET AUDIENCE
Medical Professionals in:
- Gastroenterology
- General Practice
- Hospitalist
- Internal Medicine
- OBGYN / Obstetrics & Gynecology
- Radiology
- Colorectal Surgery
- General Surgery
LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Analyze and evaluate the latest evidence and identify the strengths and limitations of head-to-head clinical trials in IBD
- Learn how to apply the most recent evidence regarding mucosal healing, neoplasia surveillance and treatment optimization including combination advanced therapy for IBD in clinical practice
- Learn about new medical treatment options in IBD and how they may affect the therapeutic landscape
- Understand the role of the multi-disciplinary team including colorectal surgeon, gastroenterologist, nutritionist, pharmacist and psychologist for the management of patients with IBD
- Review the evidence supporting the efficacy and safety of biosimilars in IBD
ACCREDITATION
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Well Assembled Meetings. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation #4008163.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
PAs may claim a maximum of 6.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum 6.5 hours.
To review the agenda and to register, click the REGISTER NOW button below
Faculty
-
Michael ChioreanCourse Director
-
Karlee AuskCourse Co-Director
-
Remo PanaccioneKeynote Speaker
15 others would like to attend.
Register Now